Table 2.
Survival analysis of PFS by various cell count cutoff values at different times using Cox proportional hazard regression.
| ALC * | Hazard Ratio (HR) | 95% CI for HR | p-Value |
|---|---|---|---|
|
Model 1: prior cycle 2 (n = 65) ALC ≥ 800 |
2.05 | 0.80, 5.28 | 0.136 |
|
Model 2: pre-surgery, all patients (n = 60) ALC ≥ 800 |
1.53 | 0.78, 3.01 | 0.220 |
|
Model 3: pre-surgery with all 4 cycles (n = 54) ALC ≥ 800 |
1.67 | 0.79, 3.54 | 0.181 |
|
Model 4: prior cycle 1 (n = 69) ALC (unit = 100 count increase) |
1.01 | 0.94, 1.08 | 0.761 |
|
Model 5: prior cycle 2 (n = 65) ALC (unit = 100 count increase) |
1.04 | 1.00, 1.07 | 0.053 |
|
Model 6: pre-surgery, all patients (n = 60) ALC (unit = 100 count increase) |
1.05 | 0.97, 1.14 | 0.221 |
|
Model 7: pre-surgery with all 4 cycles (n = 54) ALC (unit = 100 count increase) |
1.02 | 0.93, 1.12 | 0.679 |
| ANC/ALC * | Hazard Ratio (HR) | 95% CI for HR | p-Value |
|
Model 1: prior cycle 1 (n = 69) ANC/ALC ≥ 2 |
2.66 | 0.82, 8.61 | 0.104 |
|
Model 2: prior cycle 1 (n = 69) ANC/ALC ≥ 5 |
1.43 | 0.70, 2.93 | 0.327 |
|
Model 3: prior cycle 2 (n = 65) ANC/ALC ≥ 5 |
0.70 | 0.37, 1.35 | 0.287 |
|
Model 4: pre-surgery, all patients (n = 60) ANC/ALC ≥ 5 |
1.65 | 0.85, 3.22 | 0.138 |
|
Model 5: pre-surgery with all 4 cycles (n = 54) ANC/ALC ≥ 5 |
1.32 | 0.63, 2.76 | 0.468 |
|
Model 6: prior cycle 1 (n = 69) ANC/ALC ratio |
1.03 | 0.93, 1.14 | 0.620 |
|
Model 7: prior cycle 2 (n = 65) ANC/ALC ratio |
0.92 | 0.82, 1.03 | 0.135 |
|
Model 8: pre-surgery, all patients (n = 60) ANC/ALC ratio |
1.04 | 0.96, 1.13 | 0.317 |
|
Model 9: pre-surgery with all 4 cycles (n = 54) ANC/ALC ratio |
1.00 | 0.91, 1.10 | >0.999 |
| AMC | Hazard Ratio (HR) | 95% CI for HR | p-Value |
|
Model 1: prior cycle 1 (n = 69) AMC (unit = 100 count increase) |
1.05 | 0.95, 1.16 | 0.322 |
|
Model 2: prior cycle 2 (n = 64) AMC (unit = 100 count increase) |
1.15 | 1.03, 1.28 | 0.013 |
|
Model 3: pre-surgery, all patients (n = 61) AMC (unit = 100 count increase) |
1.01 | 0.90, 1.15 | 0.838 |
|
Model 4: pre-surgery with all 4 cycles (n = 54) AMC (unit = 100 count increase) |
0.95 | 0.81, 1.10 | 0.463 |
| LMR = ALC/AMC * | Hazard Ratio (HR) | 95% CI for HR | p-Value |
|
Model 1: prior cycle 1 (n = 69) LMR ≥ 2.4 |
0.87 | 0.46, 1.64 | 0.661 |
|
Model 2: prior cycle 1 (n = 69) LMR continuous |
0.94 | 0.70, 1.27 | 0.693 |
|
Model 3: prior cycle 2 (n = 64) LMR continuous |
1.17 | 0.81, 1.69 | 0.393 |
|
Model 4: pre-surgery, all patients (n = 60) LMR continuous |
1.25 | 0.77, 2.03 | 0.372 |
|
Model 5: pre-surgery with all 4 cycles (n = 54) LMR continuous |
1.40 | 0.82, 2.40 | 0.220 |
| PLR = platelets/ALC | Hazard Ratio (HR) | 95% CI for HR | p-Value |
|
Model 1: prior cycle 1 (n = 69) PLR ≥ 135 |
1.67 | 0.65, 4.24 | 0.286 |
|
Model 2: prior cycle 1 (n = 69) PLR ≥ 200 |
0.96 | 0.51, 1.81 | 0.907 |
|
Model 3: prior cycle 2 (n = 64) PLR ≥ 200 |
1.04 | 0.41, 2.69 | 0.931 |
|
Model 4: pre-surgery, all patients (n = 60) PLR ≥ 200 |
0.94 | 0.41, 2.16 | 0.885 |
|
Model 5: pre-surgery with all 4 cycles (n = 54) PLR ≥ 200 |
0.86 | 0.35, 2.13 | 0.745 |
|
Model 6: prior cycle 1 (n = 69) PLR continuous (unit = 100 count increase) |
0.94 | 0.69, 1.28 | 0.700 |
|
Model 7: prior cycle 2 (n = 64) PLR continuous (unit = 100 count increase) |
0.85 | 0.69, 1.05 | 0.131 |
|
Model 8: pre-surgery, all patients (n = 60) PLR continuous (unit = 100 count increase) |
0.96 | 0.80, 1.16 | 0.687 |
|
Model 9: pre-surgery with all 4 cycles (n = 54) PLR continuous (unit = 100 count increase) |
0.88 | 0.70, 1.10 | 0.259 |
* There were too few patients with cell counts below the cutoff value for all ALC ≥ 500, and ALC ≥ 800 pre-treatment to perform a reliable statistical analysis. There are too few patients with cell counts below the cutoff for ANC/ALC ≥ 2 prior to cycle 2 and pre-surgery to perform a reliable statistical analysis. There were too few cases with values of LMR above the cutoff for LMR ≥ 2.4 prior to cycle 2 and pre-surgery, and too few cases with a PLR below the cutoff for PLR ≥ 135 prior to cycle 2 and pre-surgery to perform a reliable statistical analysis.